For decades, patients whose small-cell lung cancer returned after initial treatment faced a narrow corridor of options and a prognosis measured in months. A randomized trial presented in September 2026 at the World Conference on Lung Cancer has widened that corridor: risvutatug rezetecan, an antibody-drug conjugate targeting the B7-H3 protein on cancer cells, nearly doubled median survival compared to the long-standing fallback chemotherapy topotecan. The findings place a new kind of hope in the hands of regulators and clinicians, and ultimately in the lives of patients for whom time has alway
Ris-Rez Shows 54% Survival Benefit Over Standard Treatment in Relapsed Lung Cancer
Patients with relapsed small-cell lung cancer, a highly aggressive cancer, now have access to a treatment that significantly extends median survival from 10.3 to 18.5 months.
An extension from 10 to 18 months represents a meaningful shift
Mark
So this is a trial of 461 people in China. Why should someone in another country care about these results?
Mimi
Because small-cell lung cancer is the same disease everywhere, and the biology doesn't change by geography. If a drug works in a well-designed trial, the mechanism works. That said, the trial was conducted in China, so there may be differences in how patients were selected or treated that affect how the results apply elsewhere.
Luke
Right—and we should note that more than 80 percent had already received immunotherapy. So this is a very specific population: people whose cancer came back after platinum chemo and PD-(L)1 inhibitors. It's not a first-line treatment.
Mark
What does the 54 percent reduction in death risk actually mean in human terms?
Mimi
It means if you're on Ris-Rez, your chances of dying in any given time period are about half what they'd be on topotecan. The median survival went from 10.3 months to 18.5 months—that's eight more months of life, on average.
Luke
Though we should be careful: median survival is what happens to the middle person. Some people lived much longer, some much shorter. And this is a median follow-up of 12.2 months, so we don't yet know the full long-term picture.
Mark
The safety data looks better too. How much of that is real versus just a difference in how the drugs work?
Mimi
The hematologic toxicities—low blood counts—are real and expected with both drugs. But Ris-Rez caused them less often and less severely. That's a genuine advantage for patients who are already compromised by prior treatment.
Luke
The trial was open-label, though, so doctors and patients knew which drug they were getting. That can introduce bias in how side effects are reported and managed. The independent review of tumor response helps, but we're still relying on investigator assessment for safety.
Mark
What happens next?
Mimi
Regulatory agencies will review these data. If approved, Ris-Rez would likely become the preferred option for people in this exact situation—relapsed small-cell lung cancer after platinum and immunotherapy.
Luke
The big question is whether the benefit holds up in other populations and whether it works as a first-line treatment. This trial is narrow by design, which is good science, but it leaves a lot of questions open.
Le Pouls
- Small-cell lung cancer is among the most lethal cancers known, and relapse after platinum-based chemotherapy has historically left patients with few options and a median survival of roughly ten months.
- The ARTEMIS-008 trial enrolled 461 patients in China—most of whom had already exhausted immunotherapy—and pitted the experimental drug Ris-Rez directly against topotecan, the current standard of care.
- Ris-Rez cut the risk of death by 54%, extended progression-free survival from 3.0 to 7.2 months, and shrank or eliminated tumors in more than half of patients, compared to just one in eight on topotecan.
- Crucially, the new drug was also safer—severe adverse events occurred in 61% of Ris-Rez patients versus 78% on topotecan, a meaningful difference for patients already weakened by prior treatment.
- Results are now before regulatory agencies and clinical practice bodies, with researchers suggesting Ris-Rez could become the new standard treatment for relapsed small-cell lung cancer.
For decades, patients whose small-cell lung cancer returned after initial treatment faced a narrow corridor of options and a prognosis measured in months. A randomized trial presented in September 2026 at the World Conference on Lung Cancer has widened that corridor: risvutatug rezetecan, an antibody-drug conjugate targeting the B7-H3 protein on cancer cells, nearly doubled median survival compared to the long-standing fallback chemotherapy topotecan. The findings place a new kind of hope in the hands of regulators and clinicians, and ultimately in the lives of patients for whom time has always been the scarcest resource.
A randomized trial of 461 patients in China has produced some of the most striking survival data seen in relapsed small-cell lung cancer in years. Risvutatug rezetecan—Ris-Rez—is an antibody-drug conjugate engineered to seek out cancer cells expressing a protein called B7-H3 and deliver a toxic payload directly to them. Tested against topotecan, the chemotherapy that has long served as the default option when this aggressive cancer returns, Ris-Rez nearly doubled how long patients lived: a median of 18.5 months compared to 10.3 months. The findings were presented in September 2026 at the World Conference on Lung Cancer.
The patients in this trial had already been through the standard gauntlet. More than 80 percent had received PD-(L)1 immunotherapy in addition to platinum-based chemotherapy before their disease progressed. For this population, options are few and prognosis is grim. The ARTEMIS-008 trial asked whether Ris-Rez could change that calculus—and the answer, across multiple measures, was yes. The drug reduced the risk of death by 54 percent, delayed disease progression more than twice as long as topotecan, and achieved tumor shrinkage or disappearance in over half of patients, versus roughly one in eight on the comparator. Disease control of any kind was reached in 90 percent of Ris-Rez patients.
Equally important was what the drug did not do. Severe side effects—predominantly blood-related toxicities like low neutrophil and platelet counts—occurred in 61 percent of patients on Ris-Rez, compared to 78 percent on topotecan. For patients already burdened by prior treatment, that difference is not merely statistical; it is felt. An independent review board, assessing tumor responses without knowledge of which treatment patients received, confirmed the benefits observed by treating physicians.
Professor Jie Wang of the National Cancer Center in Beijing, who presented the results, described Ris-Rez as a potential new standard of care for this setting. The data now move toward regulatory review, where agencies will weigh whether and how quickly this drug reaches patients for whom, until now, the question of survival has been answered in months rather than years.
A randomized trial of 461 patients in China has shown that risvutatug rezetecan, a drug designed to target a protein called B7-H3 on cancer cells, extends survival in people whose small-cell lung cancer has returned after initial treatment. The drug, known as Ris-Rez, nearly doubled the median time patients lived after enrollment—18.5 months compared with 10.3 months for those given topotecan, a chemotherapy drug that has long been the fallback option for relapsed disease. The results were presented in September 2026 at the World Conference on Lung Cancer.
Small-cell lung cancer is one of the most aggressive forms of the disease. Most patients in this trial had already received platinum-based chemotherapy and immunotherapy—more than 80 percent had been treated with PD-(L)1 inhibitors—before their cancer progressed. At that point, options narrow considerably. The ARTEMIS-008 trial tested whether Ris-Rez, an antibody-drug conjugate that delivers a toxic payload directly to cancer cells expressing B7-H3, could do better than topotecan, the standard recourse.
The numbers were striking. Ris-Rez reduced the risk of death by 54 percent. The drug also delayed disease progression longer—a median of 7.2 months versus 3.0 months with topotecan. More than half the patients given Ris-Rez saw their tumors shrink or disappear entirely, compared with just over one in eight on topotecan. Disease control—meaning tumors either shrank or remained stable—was achieved in 90 percent of Ris-Rez patients and 60 percent of those on topotecan.
What made these results particularly noteworthy was the safety profile. Ris-Rez caused severe side effects in 61 percent of patients, compared with 78 percent on topotecan. The most common serious toxicities were blood-related—low neutrophil counts, low white blood cell counts, anemia, low lymphocyte counts, and low platelet counts—but they occurred less often and less severely with the new drug. This matters because patients with relapsed cancer are often already weakened by prior treatment and cannot tolerate additional toxicity.
The trial was randomized and open-label, meaning both patients and doctors knew which treatment was being given, though an independent review board assessed tumor response without knowing which arm patients were on. That independent assessment confirmed the benefits seen by the treating physicians. The median follow-up was 12.2 months at the time of analysis, conducted in June 2026.
Professor Jie Wang of the National Cancer Center in Beijing, who presented the findings, suggested that Ris-Rez could become the new standard treatment for this population—patients whose small-cell lung cancer has progressed despite platinum-based chemotherapy. For a disease where median survival in the relapsed setting has historically been measured in months, an extension from 10 to 18 months represents a meaningful shift in what is possible. The results now move into the hands of regulatory agencies and clinical practice committees, which will determine whether and how quickly this drug becomes available to patients facing this diagnosis.
Citations marquantes
Ris-Rez demonstrated a statistically significant and clinically meaningful overall survival benefit over topotecan in patients with SCLC that progressed after platinum-based therapy, with a favorable safety profile.— Professor Jie Wang, National Cancer Center, Beijing
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine